VERASTEM INC (VSTM)
US92337C2035 - Common Stock
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Verastem Oncology to Participate in Upcoming Investor Conferences
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference
VSTM Stock Earnings: Verastem Beats EPS, Beats Revenue for Q2 2024
VSTM stock results show that Verastem beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news to start the day with!
Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
Bragar Eagel & Squire, P.C. Is Investigating Verastem, Helios, and LegalZoom and Encourages Investors to Contact the Firm
Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. ("Verastem" or the "Company") (NASDAQ: VSTM). Such investors are...
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. ("Verastem" or the "Company") (NASDAQ: VSTM). Such investors are...
Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. ("Verastem" or the "Company") (NASDAQ: VSTM). Such investors are...
GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation
/PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China's...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. ("Verastem" or the "Company") (NASDAQ: VSTM). Such investors are...
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
/PRNewswire/ -- After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation...
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
/CNW/ -- After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may...
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Verastem, Inc. (VSTM)
7 F-Rated Stocks to Avoid at All Costs in June
The stock market is doing well this year, so it would be a tragedy to own F-rated stocks. Here are some key stocks to avoid in June.
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
/PRNewswire/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer...
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
/CNW/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. ("Verastem" or the "Company") (NASDAQ: VSTM). Such investors are...